Evidence map›Paper›PMID 39430196›Full record

ArticleKidney international reports2024

Canagliflozin Pharmacokinetics at Steady State in Patients on Maintenance Hemodialysis.

Thomas A Mavrakanas, Amélie Marsot, Efrosyne Tsirella, Norka Rios, Ari Gritsas, Rita S Suri

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05309785 (Safety and Efficacy of Canagliflozin in Advanced CKD), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05309785 phase4completednot on this map

Safety and Efficacy of Canagliflozin in Advanced CKD

TypeinterventionalSponsorMcGill University Health Centre/Research Institute of the McGill University Health CentreRan2022 to 2026Enrolled34ConditionsESRD, CKD Stage 4, CKD Stage 5ArmsInvokana 300 mg and 100 mg tablet
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Thomas A MavrakanasDivision of Nephrology, Department of Medicine, McGill University Health Center, Montreal, Quebec, Canada.
Amélie MarsotFaculty of Pharmacy, University of Montreal, Montreal, Quebec, Canada.
Efrosyne TsirellaResearch Institute of the McGill University Health Center, Montreal, Quebec, Canada.
Norka RiosResearch Institute of the McGill University Health Center, Montreal, Quebec, Canada.
Ari GritsasResearch Institute of the McGill University Health Center, Montreal, Quebec, Canada.
Rita S SuriDivision of Nephrology, Department of Medicine, McGill University Health Center, Montreal, Quebec, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

canagliflozinhemodialysispharmacokinetics

Identifiers

PMID39430196
PMCPMC11489451

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.